New inhaled drug shows promise against asthma, allergies

by Dennis Thompson, Healthday Reporter
New inhaled drug shows promise against asthma, allergies
Quilizumab quells production of protein that triggers reaction to allergens, researchers report.

A new inhaled medication has the potential to treat mild asthma and allergies by interrupting the production of an immune system protein that triggers allergic reactions, a new study reports.

The , quilizumab, targets the blood cells that produce a protein called immunoglobulin type E (IgE), that serves a key role in allergies.

Quilizumab lowered total levels of IgE in the blood of people with allergies and , and kept them low for a month, researchers report in the July 2 issue of the journal Science Translational Medicine.

"The subjects who received the drug not only had a reduction in their total IgE level, it also seemed to block production of new IgE in response to the allergen they inhaled," said study co-author Dr. Jeffrey Harris, principal medical director of immunology, tissue growth and repair for the Genentech, which produces quilizumab and funded the study.

However, one expert noted that the drug has yet to prove itself against moderate to severe asthma.

IgE is present in minute amounts in the body, but plays a major role in allergic diseases.

The protein binds to allergens upon first exposure, and then triggers the release of inflammatory substances when a person is re-exposed to the same allergens, creating an allergic response and, potentially, an .

There currently is only one medication that specifically targets IgE, an injectable drug called omalizumab that binds to the protein in the bloodstream and neutralizes it.

Experts say quilizumab has the potential to replace the existing drug because it is more convenient and longer lasting.

Patients on omalizumab must receive one to three injections every two to four weeks, Harris said. If quilizumab proves as effective as it was in this early study, patients may only need to inhale a dose every three months or so.

"This could be very exciting, if it works," said Dr. Bradley Chipps, an allergist in Sacramento, Calif. "It could be even more effective than omalizumab, which binds to IgE after it's produced. This drug tries to keep it from being produced."

Researchers tested the drug in one group of 36 allergy patients and another group of 29 people with mild asthma, randomly giving patients either quilizumab or an inactive placebo. In the study, patients were exposed to allergens and then blood samples were taken to measure levels of IgE in their bloodstream.

Quilizumab reduced overall levels of IgE, and also reduced the amount of IgE that specifically targeted the allergens to which patients were exposed, the study found. Further, the IgE levels remained lower for at least six months following the patients' last dose of the drug.

However, the drug did not have a significant effect on the early and late asthmatic responses in after they were exposed to an allergen, compared to placebo, said Dr. Myron Zitt, an allergist and associate professor at State University of New York, Stony Brook.

"It is interesting because it is a new drug that blocks IgE production, but when you look at the figures, it's not so impressive," Zitt said, adding that quilizumab will have to display effectiveness in treating people with moderate to severe if it stands a chance of replacing either omalizumab or standard steroid treatment.

Study author Harris said a follow-up clinical trial involving 560 people with more is underway, with results likely available next year.

More information: "Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production," by G.M. Gauvreau et al. stm.sciencemag.org/lookup/doi/… scitranslmed.3008961

add to favorites email to friend print save as pdf

Related Stories

Food allergies: A new, simple method to track down allergens

Jul 02, 2014

Although food allergies are common, sufferers often don't know exactly what in foods cause their allergic reactions. This knowledge could help develop customized therapies, like training the body's immune system to respond ...

Eliminating the source of asthma-causing immune molecules

May 10, 2010

Asthma and other allergic diseases are caused by inappropriate immune responses. Soluble IgE molecules, produced by immune cells known as B cells, are key immune mediators of these diseases. Therapeutic targeting of IgE in ...

Early-life probiotics reduce allergies, not asthma

Aug 20, 2013

(HealthDay)—Probiotic exposure in early life may reduce total immunoglobulin E level (IgE) and protect against atopic sensitization, but does not seem to protect against asthma/wheezing, according to a ...

Recommended for you

Multiple allergic reactions traced to single protein

5 hours ago

Johns Hopkins and University of Alberta researchers have identified a single protein as the root of painful and dangerous allergic reactions to a range of medications and other substances. If a new drug can ...

Gene-environment connection seen in peanut allergy study

Dec 15, 2014

(HealthDay)—Infants of a particular generation born in Australia to Asian-born parents appeared to have an increased risk of peanut allergy compared with those of Australian-born parents, according to research ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.